|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2005-12-26
|
|
pubmed:abstractText |
The purpose of this study was to determine the feasible dose of gemcitabine when administered as a fixed dose rate infusion (10 mg/m(2)/min) on a weekly schedule to Japanese patients with unresectable advanced pancreatic cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0368-2811
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
35
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
733-8
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16303793-Aged,
pubmed-meshheading:16303793-Antimetabolites, Antineoplastic,
pubmed-meshheading:16303793-Deoxycytidine,
pubmed-meshheading:16303793-Dose-Response Relationship, Drug,
pubmed-meshheading:16303793-Drug Administration Schedule,
pubmed-meshheading:16303793-Female,
pubmed-meshheading:16303793-Humans,
pubmed-meshheading:16303793-Infusions, Intravenous,
pubmed-meshheading:16303793-Male,
pubmed-meshheading:16303793-Middle Aged,
pubmed-meshheading:16303793-Pancreatic Neoplasms,
pubmed-meshheading:16303793-Survival Rate
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Phase I study of fixed dose rate infusion of gemcitabine in patients with unresectable pancreatic cancer.
|
|
pubmed:affiliation |
Division of Hepatobiliary and Pancreatic Medical Oncology, National Cancer Center Hospital East, Kashiwa, Chiba 277-8577, Japan. jfuruse@east.ncc.go.jp
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
